PitchSend

argenx SE Investor Day Presentation Deck

Phase 2 Multifocal Motor Neuropathy Trial Design Patient Population Trial to enroll approximately 45 MMN patients ● ● ● ● Probable or definite MMN (per EFNS/PNS 2010) Independent adjudication committee Stable IVlg regimen IVlg treatment dependent ili argenx 4-10 weeks IVIg Monitoring Period Randomization (1:1:1) Total Duration: 16 weeks ARGX-117 Dose Regimen 1 (N=15) ARGX-117 Dose Regimen 2 (N=15) Placebo (N=15) ARGX-117 Open-label Extension Trial on track to start by end of 2021 Key Outcome Measures Safety and tolerability Time to IVlg re-treatment Measures of peripheral muscle strength: grip strength, mMRC sum score, 9-HPT, MMN-RODS Patient-reported outcomes PK, PD, biomarkers 67

View entire presentation